Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbetocin versus oxytocin for prevention of retained placenta after mid-trimester medical termination or fetal demise induction
ACTRN12626000028303Phase 4Not yet recruiting
- Sponsor
- King Edward Memorial Hospital
- Start
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in retained placenta comparing Intravenous carbetocin with Intramuscular oxytocin (2 arms). Primary endpoint: Incidence of placental retention. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
carbetocinoxytocin
03
Conditions
retained placenta
Beyond the preview
Go deeper on ACTRN12626000028303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000028303.